Status:
COMPLETED
hCG-activated PBMC-therapy in RIF Patients
Lead Sponsor:
SCARM Institute, Tabriz, Iran
Conditions:
Recurrent Implantation Failure
Eligibility:
FEMALE
20-45 years
Phase:
NA
Brief Summary
Despite the many research done in the field of infertility and in vitro fertilization (IVF), more than half of the embryos transmitted in the IVF and intracytoplasmic sperm injection (ICSI) do not imp...
Detailed Description
248 women with the history of implantation failure volunteered to receive PBMC-therapy. After immunologic consultation and doing flow cytometry analysis, 100 women with at least three IVF/ET failure w...
Eligibility Criteria
Inclusion
- All patients were evaluated in accordance with the following inclusion and exclusion criteria;
- Having at least three implantation failures following IVF
- Having primary infertility
- Age under 45 years old
- Having regular menstrual cycles
- BMI under 30
Exclusion
- Having polycystic ovary syndrome
- The presence of uterine pathology;
- Poor ovarian reserve
- Having chromosomal abnormalities
- Presence of auto anti-bodies such as anti-TPO, anti-TG, ACA, APA, ANA, and anti-dsDNA
- Presence of mutations involving the coagulation system such as deficiency of factor XII, Pro C, Pro S
- Positive HIV, HCV or HBV tests
Key Trial Info
Start Date :
October 7 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 11 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03267797
Start Date
October 7 2017
End Date
July 11 2019
Last Update
August 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Valiasr Hospital
Tabriz, Iran